Anzeige
Mehr »
Login
Freitag, 19.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Kurze Gold-Preis-Konsolidierung zum Einstieg in diese Aktie nutzen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0D83X | ISIN: US98385L1026 | Ticker-Symbol: N/A
1-Jahres-Chart
NOVACCESS GLOBAL INC Chart 1 Jahr
5-Tage-Chart
NOVACCESS GLOBAL INC 5-Tage-Chart

Aktuelle News zur NOVACCESS GLOBAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
01.03.NovAccess Global Inc.: NovAccess Global Provides Business Updates and Announces Scheduling of Annual Meeting of Shareholders309CLEVELAND, OH / ACCESSWIRE / March 1, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today provided an update on business...
► Artikel lesen
28.02.NovAccess Global Inc. - 8-K, Current Report1
27.02.NovAccess Global Inc. - 10-Q, Quarterly Report1
15.02.NovAccess Global Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB-
09.02.NovAccess Global Inc. - 10-K, Annual Report-
06.02.NovAccess Global Inc. - 8-K, Current Report-
22.01.NovAccess Global Inc. - 8-K, Current Report1
02.01.NovAccess Global Inc. - 8-K, Current Report1
02.01.NovAccess Global Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT4051
02.01.NovAccess Global jumps on announcing $10.7 million financing2
02.01.NovAccess Global Inc.: NovAccess Global Announces $10.7 Million Financing320Establishes Strong Financial Base To Advance Development of Novel Cancer ImmunotherapiesCLEVELAND, OH / ACCESSWIRE / January 2, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing...
► Artikel lesen
21.12.23NovAccess Global Inc. - 8-K, Current Report2
01.12.23The Investor Summit: NovAccess Global Inc. to Present at the December 7th Virtual Investor Summit1.390Cleveland, Ohio--(Newsfile Corp. - December 1, 2023) - NovAccess Global Inc. (OTCQB: XSNX) announced today it will be presenting at the December 7th, 2023 virtual Investor Summit.Event:December 7th...
► Artikel lesen
10.11.23NovAccess Global Inc.: NovAccess Global Appoints Dr. Roscoe M. Moore, Jr. to Scientific Advisory Board2.402CLEVELAND, OH / ACCESSWIRE / November 10, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a preclinical biomedical company developing novel immunotherapies for brain tumor patients, today announced the appointment...
► Artikel lesen
27.07.23NovAccess Global Inc.: NovAccess Global Partners with BCN Biosciences to Expand Immunotherapy Platform439Development Begins on Fourth Generation of Primary Drug TLR-AD1 Targeting CNS TumorsPotential for Improved Outcomes for Cancer Patients in the $100 Billion a Year Immune Oncology MarketCLEVELAND, OH...
► Artikel lesen
13.07.23NovAccess Global Inc.: NovAccess Global to Participate in National Brain Tumor Society's Annual Glioblastoma Awareness Day398CLEVELAND, OH / ACCESSWIRE / July 13, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that its Chief Executive...
► Artikel lesen
16.06.23NovAccess Global Inc.: NovAccess Global Partners with CKN Ventures to Expand its New AI-driven Precision Medicine Division639CLEVELAND, OH and BANGKOK, THAILAND / ACCESSWIRE / June 16, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced...
► Artikel lesen
01.06.23NovAccess Global Inc.: NovAccess Global Launches Precision Medicine Division Using AI, Big Data and Predictive Technologies to Accelerate Personalized Healthcare Therapies362CLEVLAND, OH / ACCESSWIRE / June 1, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the formation of its Precision...
► Artikel lesen
11.05.23NovAccess Global Inc.: NovAccess Global Lead Scientist Published in High-Profile Medical Journal for Cancer Vaccine Advancements471Report Details Promise of Adaptive Cancer Immunotherapy in Treating Highly Malignant Brain TumorsRecent Achievements for Glioblastoma/Brain Tumor Treatment to be Addressed in Upcoming Presentation at...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1